Skip to main content
Clinical Trials/NCT00858520
NCT00858520
Unknown
Not Applicable

Serum, Plasma, DNA and Tissue Bank of Patients With Chronic Obstructive Pulmonary Disease, Lung Cancer and Smoking Controls.

KU Leuven1 site in 1 country2,000 target enrollmentOctober 2007

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Chronic Obstructive Pulmonary Disease
Sponsor
KU Leuven
Enrollment
2000
Locations
1
Primary Endpoint
Serological, cytological, histological and genetic analysis of biomarkers or genes which are involved in the pathogenesis of COPD/Emphysema/Lungcancer.
Last Updated
12 years ago

Overview

Brief Summary

A biobank of Serum, plasma, DNA samples together with clinical information including specific questionnaires, complete pulmonary function and chest CT-scan, is prospectively collected in patients seen at the investigators' clinical service.

The objective is to study candidate gene pathways in COPD and or lung cancer and to associate them with the clinical characteristics and phenotypes of COPD/emphysema and lung cancer.

In subgroups of well characterised patients, other biological materials are also collected (lung tissue biopsies, peripheral blood mononuclear cells).

Detailed Description

All patients with a smoking history of at least 15 pack years, an minimal age of 50 years and an recent available CT scan are enrolled. All subjects with a diagnosis of lung cancer are also collected (irrespective of age and smoking behavior). In addition the investigators collect: * specific questionnaires (MRC, CCQ and smoking history) * medical and professional history * complete pulmonary function (spirometry, bodyplethysmography and diffusing capacity) * serum, plasma and DNA samples. In specific subgroups the investigators also collect: * Peripheral blood mononuclear cells * Lung tissue - if available - from a surgical procedure (lung transplantation or lobectomy)

Registry
clinicaltrials.gov
Start Date
October 2007
End Date
December 2019
Last Updated
12 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
KU Leuven
Responsible Party
Principal Investigator
Principal Investigator

Marc Decramer

Prof.Dr.

KU Leuven

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Serological, cytological, histological and genetic analysis of biomarkers or genes which are involved in the pathogenesis of COPD/Emphysema/Lungcancer.

Time Frame: 0-1-3-6 years

All cases are prospectively collected in University hospital Leuven, Belgium. Of enrolled subjects data are collected at 0,1,3 and 6 years interval

Study Sites (1)

Loading locations...

Similar Trials